Ultrasound findings after medication management of early pregnancy loss

Atrio is the associate dean of Clinical Research at Alice L. Walton School of Medicine in Bentonville, Arkansas. Fjerstad is the senior director of Medical Affairs at GenBioPro. Prager is a professor in the Department of Obstetrics and Gynecology and the director of the Complex Family Planning Division at the University of Washington in Seattle.

Disclosures: Atrio is a part-time medical director for Exeltis. Prager is a trainer for Nexplanon and an adviser for Roon. Fjerstad is a consultant for GenBioPro.

Purpose of review

This narrative review describes sonographic findings within the uterine cavity after medication treatment of first-trimester miscarriage and synthesizes the literature addressing the clinical significance of these findings after expectant or medication management.

Recent findings

Following a miscarriage, the uterine cavity seldom appears sonographically “empty” within the first weeks. Studies evaluating whether endometrial thickness predicts adverse outcomes, including heavy bleeding or the need for subsequent intervention, have not identified a validated threshold. In patients without significant pain, heavy bleeding, fever, or other concerning symptoms, additional treatment is generally unnecessary regardless of the sonographic appearance of heterogeneous intrauterine contents.

Summary

A wide range of ultrasound findings may be observed after successful treatment of early pregnancy loss, including a thickened endometrium and heterogeneous intrauterine material. If the gestational sac and embryo or fetus has been expelled and the patient is clinically stable and asymptomatic, no established ultrasound criteria alone indicate the need for intervention. Clinical management should be guided primarily by symptoms and overall patient status rather than by ultrasound appearance in isolation.

Introduction

Before ultrasound became routinely available in obstetrics and gynecology, miscarriage was diagnosed largely based on symptoms. If a patient presented in the first trimester with bleeding and cramping, the presumptive diagnosis was threatened or inevitable spontaneous abortion. If tissue passed spontaneously and symptoms resolved, intervention was often unnecessary. Persistent or heavy bleeding, however, commonly prompted dilation and curettage or vacuum aspiration for both diagnostic and therapeutic purposes.

The advent of transvaginal ultrasonography transformed the diagnosis and management of early pregnancy complications. In the late 1980s, Ilan Timor-Tritsch and others advanced the field of “sono-embryology,” enabling more accurate diagnosis of early embryonic abnormalities and ectopic pregnancy.¹ By the 1990s, most hospitals in the United States had access to transvaginal ultrasound, and the use of gynecologic and obstetric ultrasound became widespread in both training programs and clinical practice.² Today, ultrasound is routinely used to assess gestational age, viability, pregnancy location, placentation, multiple gestation, and early fetal development.

Early pregnancy loss (EPL) is the most common complication of pregnancy. Approximately 750,000 to 1 million individuals in the United States experience miscarriage each year,³ and sporadic miscarriage affects 1 in 4 women.⁴

This review focuses on sonographic findings after first-trimester EPL, particularly following medication management, and examines the extent to which ultrasound findings should influence posttreatment clinical decision-making.

Early pregnancy loss and missed miscarriage

This discussion is limited to the first trimester, defined here as up to 13 to 14 weeks of gestation. The most common type of spontaneous abortion presents with vaginal bleeding, uterine cramping, an open cervical os, and sometimes a decrease in pregnancy-related symptoms, such as breast tenderness or nausea.^5.

In contrast, anembryonic pregnancy and embryonic demise may occur with minimal or no symptoms, sometimes limited to light spotting or mild bleeding. These more clinically silent entities are often referred to as “missed miscarriage,” a term used in a recent large multicenter randomized trial from the United Kingdom.⁶ The American College of Obstetricians and Gynecologists (ACOG), however, uses the broader term early pregnancy loss to encompass anembryonic pregnancy and embryonic demise.⁷

Anembryonic pregnancy refers to the development of an intrauterine gestational sac without the formation of a visible embryo, or to a pregnancy in which an embryo developed but was subsequently reabsorbed.⁸ Trophoblastic tissue may continue to function, and the gestational sac may continue to enlarge, albeit more slowly than in a viable pregnancy.⁹

Embryonic demise in the first trimester is characterized by cessation of embryonic or fetal development, loss of previously observed cardiac activity, or absence of cardiac activity once specific sonographic criteria are met. In both settings, the cervix is typically closed, and bleeding may be minimal or absent.¹⁰

Medication management of missed miscarriage

Both the ACOG Practice Bulletin⁷ on EPL and the Society of Family Planning (SFP) Clinical Recommendation¹¹on medication management for EPL discuss expectant, medication, and procedural treatment options for miscarriage. ACOG recommends mifepristone 200 mg orally, followed 24 hours later by misoprostol 800 µg vaginally for medication management^.7 SFP recommends mifepristone 200 mg orally, followed 7 to 48 hours later by misoprostol 800 µg administered either vaginally or buccally.¹¹

Ultrasound findings after miscarriage

A wide range of sonographic findings may be observed after expulsion of the conceptus, including endometrial thickening and heterogeneous intrauterine material. In asymptomatic patients who have successfully passed the gestational sac, these findings rarely justify medical or surgical intervention, additional testing, or ongoing monitoring in the absence of concerning clinical symptoms.

Historically, a “complete” miscarriage was equated with sonographic demonstration of an “empty” uterus. This framework assumed that a complete spontaneous abortion should show an empty uterus, whereas echogenic debris, fluid, or a thickened endometrium suggested incomplete abortion or retained products.¹² This paradigm persisted for years, despite limited evidence that such findings reliably predict clinically important outcomes.

For many years, an endometrial thickness of 15 mm or greater—usually measured within 7 to 14 days after treatment—was commonly used as a threshold to define incomplete miscarriage or retained products of conception (RPOC).^12-14However, subsequent studies have challenged the clinical utility of this approach.

One of the earliest prospective studies examining transvaginal imaging after uterine evacuation was published in 2001.¹⁵In that study, asymptomatic patients underwent pelvic ultrasound within 6 days after dilation and aspiration, spontaneous abortion, or missed miscarriage. Only 23% had a thin, regular midline stripe measuring less than 7 mm. Half had a hyperechoic midline stripe measuring 7 mm to 19 mm, and 27% had irregular echogenic intrauterine material with an endometrial thickness of at least 20 mm. Importantly, there was no correlation between ultrasound appearance and gravidity, parity, gestational age, or type of abortion. Among patients with heterogeneous intrauterine material measuring 18 mm to 61 mm, follow-up imaging after the next menstrual period demonstrated spontaneous resolution and a normal-appearing endometrial stripe in asymptomatic individuals. The authors concluded that the uterus is capable of spontaneously expelling or reabsorbing substantial amounts of decidua, clot, and fluid after abortion or miscarriage. In the week following a first-trimester abortion of any type, the uterus is rarely empty. Up to 77% of uncomplicated cases present with thick, heterogeneous intrauterine material.¹⁵

As medication abortion became more common in the United States, clinicians increasingly encountered persistent sonographic heterogeneity despite successful passage of the embryo or gestational sac. Follow-up ultrasound performed within 14 days after mifepristone administration often revealed findings that historically would have been interpreted as incomplete evacuation. Research, however, consistently found that clinical intervention should not be based solely on endometrial thickness. Rather, treatment decisions should be guided by symptoms and other clinical indicators. Endometrial thickness after medical management of early pregnancy loss does not predict subsequent need for surgical intervention, and there is no validated sonographic threshold above which intervention is universally warranted.^16,17

Assessment for RPOC remains variable across institutions and clinicians. Although some providers continue to use an endometrial thickness of 15 mm or greater at 2 weeks as a sonographic criterion suggestive of RPOC, this threshold has not been validated.¹⁸ Moreover, pain, ongoing bleeding, or heavy bleeding are themselves sufficient reasons to evaluate further, regardless of ultrasound findings.¹⁹ A systematic review assessing the diagnostic accuracy of an endometrial thickness of at least 15 mm concluded that no single imaging marker consistently identifies RPOC and that current evidence does not support recommending a diagnostic cutoff for endometrial thickening.²⁰

A retrospective study of 91 patients with first-trimester miscarriage and suspected RPOC who underwent surgical evacuation with histopathologic analysis found that hyperechoic material combined with vaginal bleeding was the most significant predictor of retained products.²¹ Endometrial thickness did not significantly differ between patients with confirmed chorionic villi and those with decidual shedding alone. Following these findings, the investigators revised their institutional approach so that surgical evacuation would be reserved for symptomatic patients with a combination of clinical and sonographic findings rather than solely ultrasound findings, such as endometrial thickening, clots, or fluid pockets.²¹

Taken together, the available evidence supports a patient-centered, symptom-based approach to management after early pregnancy loss. No clear or validated ultrasound threshold mandates intervention in patients who are asymptomatic.^18-21 Thickened endometrium and heterogeneous intrauterine material are common and expected findings during the physiologic process of miscarriage resolution.^16,18,20

Utility of color Doppler

Transvaginal ultrasound findings such as a thin endometrial stripe vs a thickened endometrium with heterogeneous intrauterine contents are not, in isolation, sufficient to guide intervention after treatment of missed miscarriage. Some authors have proposed the use of color Doppler sonography to differentiate benign intrauterine contents from RPOC. However, retained products display variable vascularity, ranging from avascular to markedly vascular.²² Accordingly, Doppler findings must also be interpreted in the broader clinical context.

In a prospective cohort study of 2627 patients following first-trimester miscarriage, 40 patients (1.5%) were found to have enhanced myometrial vascularity on color Doppler imaging. Of the 31 patients who chose expectant management, none required emergency intervention, including surgery, transfusion, or embolization, and none developed sepsis.²³ These findings further support conservative management when the patient is clinically stable.

Illustrative case

An obstetrics-gynecology physician evaluates a 30-year-old gravida 2, para 1 patient at her first prenatal visit. Transvaginal ultrasound demonstrates an embryo measuring 13 mm, corresponding to 7 weeks and 6 days, with no cardiac activity. The patient reports light bleeding and has a closed cervical os. After counseling regarding the diagnosis of embryonic demise and discussing expectant, medication, and procedural management options, the patient initially requests time to consider her choices. During a follow-up phone call 2 days later, she elects medication management and is prescribed mifepristone 200 mg orally, followed 24 hours later by misoprostol 800 µg buccally.

At follow-up 1 week later, the patient reports that she took the medications as prescribed. Following the misoprostol, she experienced several hours of bleeding somewhat heavier than her normal menses, followed by light bleeding similar to the last days of a menstrual period. She reports no current pain and feels well. Her pregnancy symptoms, including breast tenderness and nausea, have resolved. Based on this clinical history, the clinician reassures her that treatment was successful. At the patient’s request, an ultrasound is performed and demonstrates a thickened endometrium with heterogeneous intrauterine material (Figure 1).

The clinician explains that the embryo has been expelled and that the remaining sonographic findings likely reflect uterine involution. She explains in language appropriate to the patient’s understanding that the decidual tissue and blood clot will resolve or reabsorb spontaneously over the following weeks. She advises the patient that no further follow-up is medically necessary, although also recommending that she call if she experiences heavy bleeding, pain, or fever. The patient chooses to return 2 weeks later for additional reassurance.

At the follow-up visit, the patient reports having had a subsequent menstrual period and is no longer bleeding. Repeat transvaginal ultrasound demonstrates resolution of the previously noted intrauterine material (Figure 2). The physician confirms that no additional treatment is indicated. This case illustrates a central principle in post-miscarriage care: Treat the patient, not the ultrasound.

Clinical lessons from the case

1. Ultrasound heterogeneity is a common finding after miscarriage and does not, in itself, represent pathology.
2. Symptoms guide management.
3. Repeat imaging is often unnecessary.

Clinical Management Framework (in context of patient -centered care)

When to reassure:

1. The gestational sac/embryo was expelled.
2. Patient is asymptomatic for heavy bleeding, pain, or other concerning clinical findings.

When to consider further intervention based on consultation with the patient:

1. The gestational sac/embryo is still visible on ultrasound.
2. Bleeding has not decreased to a light menstrual period/spotting.
3. Patient is experiencing persistent cramping.

When to intervene:

1. Patient is experiencing persistently or erratically heavy bleeding.
2. Patient is experiencing pain or fever.

Conclusion

After an early miscarriage, once an ultrasound or the clinical course confirms expulsion of the gestational sac and embryo or fetus, ancillary sonographic findings such as endometrial thickening and heterogeneous intrauterine material should be interpreted in the context of the patient’s symptoms and overall condition rather than as isolated indications for intervention. Ongoing pain, excessive, persistent or erratic bleeding, or fever necessitate evaluation and may alone be the basis for intervention.

Physiologic post-miscarriage changes commonly include uterine involution, decidual shedding, fluid collections, and blood clot within the uterine cavity. Current evidence does not support intervention solely because an ultrasound demonstrates a thickened endometrium or heterogeneous intrauterine material in an otherwise asymptomatic patient who has successfully passed the pregnancy tissue. Further research may improve understanding of the normal spectrum of post miscarriage sonographic findings and clarify whether any imaging characteristics consistently predict the need for intervention.

Key points

Sonographic heterogeneity and endometrial thickening are common after successful treatment of early pregnancy loss and do not, by themselves, indicate treatment failure.

No validated endometrial thickness threshold reliably predicts adverse outcomes or the need for surgical intervention.

Clinical symptoms—particularly heavy or persistent bleeding, pain, and fever—should guide posttreatment management.

In asymptomatic, clinically stable patients who have passed the gestational sac and embryo or fetus, expectant observation is usually appropriate even when ultrasound shows persistent intrauterine material.

Shared decision-making and patient autonomy remain central to management.

Acknowledgments

The authors wish to acknowledge the work of Brandi K. Howard, PhD; Stephanie Sober, MD; and Matthew F. Reeves, MD.

References

1. Timor-Tritsch IE, Monteagudo A, Peisner DB. High-frequency transvaginal sonographic examination for the potential malformation assessment of the 9-week to 14-week fetus. J Clin Ultrasound. 1992;20(4):231-238. doi:10.1002/jcu.1870200403

2. Campbell S. A short history of sonography in obstetrics and gynaecology. Facts Views Vis Obgyn. 2013;5(3):213-229

3. Bardos J, Hercz D, Friedenthal J, Missmer SA, Williams Z. A national survey on public perceptions of miscarriage. Obstet Gynecol. 2015;125(6):1313-1320. doi:10.1097/AOG.0000000000000859

4. Hardy K, Hardy PJ. 1(st) trimester miscarriage: four decades of study. Transl Pediatr. 2015;4(2):189-200. doi:10.3978/j.issn.2224-4336.2015.03.05

5. University of California Davis Health Department of Obstetrics and Gynecology. Early pregnancy and miscarriage center. Accessed September 4, 2026. https://health.ucdavis.edu/obgyn/specialties/family-planning/early-pregnancy-miscarriage/signs-early-miscarriage#:~:text=Early%20miscarriage%20is%20the%20loss%20of%20a,you%20should%20contact%20a%20doctor%20right%20away

6. Chu JJ, Devall AJ, Beeson LE, et al. Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;396(10253):770-778. doi:10.1016/S0140-6736(20)31788-8

7. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 200: Early Pregnancy Loss. Obstet Gynecol. 2018;132(5):e197-e207. doi:10.1097/AOG.0000000000002899

8. Gupta N, Angtuaco TL. Embryosonology in the first trimester of pregnancy. Ultrasound Clinics. 2007;2(2):175-185. doi:10.1016/j.cult.2007.07.006

9. Carlson K, Tafti D. Anembryonic pregnancy. In: StatPearls. StatPearls Publishing; 2026. Accessed July 2, 2026. https://www.ncbi.nlm.nih.gov/books/NBK499938/

10. Dooley WM, De Braud L, Thanatsis N, Memtsa M, Jauniaux E, Jurkovic D. Predictive value of presence of amniotic sac without visible embryonic heartbeat in diagnosis of early embryonic demise. Ultrasound Obstet Gynecol. 2021;57(1):149-154. doi:10.1002/uog.23533

11. Tarleton JL, Benson LS, Moayedi G, et al; Society of Family Planning Clinical Affairs Committee. Society of Family Planning Clinical Recommendation: medication management for early pregnancy loss. Contraception. 2025;144:110805. doi:10.1016/j.contraception.2024.110805

12. Nyberg DA, Abuhamad A, Ville Y. Ultrasound assessment of abnormal fetal growth. Semin Perinatol. 2004;28(1):3-22. doi:10.1053/j.semperi.2003.10.010

13. Wong SF, Lam MH, Ho LC. Transvaginal sonography in the detection of retained products of conception after first-trimester spontaneous abortion. J Clin Ultrasound. 2002;30(7):428-432. doi:10.1002/jcu.10086

14. Ustunyurt E, Kaymak O, Iskender C, Ustunyurt OB, Celik C, Danisman N. Role of transvaginal sonography in the diagnosis of retained products of conception. Arch Gynecol Obstet. 2008;277(2):151-154. doi:10.1007/s00404-007-0436-z

15. Bar-Hava I, Aschkenazi S, Orvieto R, et al. Spectrum of normal intrauterine cavity sonographic findings after first-trimester abortion. J Ultrasound Med. 2001;20(12):1277-1281. doi:10.7863/jum.2001.20.12.1277

16. Reeves MF, Lohr PA, Harwood BJ, Creinin MD. Ultrasonographic endometrial thickness after medical and surgical management of early pregnancy failure. Obstet Gynecol. 2008;111(1):106-112. doi:10.1097/01.AOG.0000296655.26362.6d

17. Cowett AA, Cohen LS, Lichtenberg ES, Stika CS. Ultrasound evaluation of the endometrium after medical termination of pregnancy. Obstet Gynecol. 2004;103(5):871-875. doi:10.1097/01.AOG.0000124782.69622.48

18. Sawyer E, Ofuasia E, Ofili-Yebovi D, Helmy S, Gonzalez J, Jurkovic D. The value of measuring endometrial thickness and volume on transvaginal ultrasound scan for the diagnosis of incomplete miscarriage. Ultrasound Obstet Gynecol. 2007;29(2):205-209. doi:10.1002/uog.3914

19. Blyth U, Fourie H, Akinola L, Smith C, Melo P, Granne I. Definition and diagnostic criteria of retained products of conception following first-trimester pregnancy loss: a systematic review. Hum Fertil (Camb). 2025;28(1):2522054. doi:10.1080/14647273.2025.2522054

20. Hamel CC, van Wessel S, Carnegy A, et al. Diagnostic criteria for retained products of conception-a scoping review. Acta Obstet Gynecol Scand. 2021;100(12):2135-2143. doi:10.1111/aogs.14229

21. Abbasi S, Jamal A, Eslamian L, Marsousi V. Role of clinical and ultrasound findings in the diagnosis of retained products of conception. Ultrasound Obstet Gynecol. 2008;32(5):704-707. doi:10.1002/uog.5391

22. Kamaya A, Petrovitch I, Chen B, Frederick CE, Jeffrey RB. Retained products of conception: spectrum of color Doppler findings. J Ultrasound Med. 2009;28(8):1031-1041. doi:10.7863/jum.2009.28.8.1031

23. Grewal K, Al-Memar M, Fourie H, Stalder C, Timmerman D, Bourne T. Natural history of pregnancy-related enhanced myometrial vascularity following miscarriage. Ultrasound Obstet Gynecol. 2020;55(5):676-682. doi:10.1002/uog.21872